L Setti

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Rama Jain, Michelle Mathur, Jiong Lan et al. · Journal of Medicinal Chemistry · 2015 · 82 citations · Full text

Drug Target, Chemoprevention Strategy, Rsk Kinase Family +17

Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity

Kevin R. Guertin, L Setti, Lida Qi et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 47 citations · Full text

Biochemistry, Medicine, Natural Sciences +9

Design and Discovery of <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

Gisele Nishiguchi, Alice Rico, Huw R. Tanner et al. · Journal of Medicinal Chemistry · 2017 · 44 citations · Full text

Drug Target, Kras Mutant Tumors, Kinase Inhibitors +17

Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Savithri Ramurthy, Benjamin R. Taft, Robert J. Aversa et al. · Journal of Medicinal Chemistry · 2019 · 38 citations · Full text

Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors

Paul A. Barsanti, Yue Pan, Yipin Lu et al. · ACS Medicinal Chemistry Letters · 2014 · 27 citations · Full text

Pharmaceutical Science, Drug Target, Indole Moiety +19